Litcius/Paper detail

LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, Christine Chevreau, Nicolas Penel, Didier Cupissol, P. Boudou Rouquette, François Bertucci, Corinne Balleyguier, Valérie Lebrun-Ly, Jean‐Yves Blay, Elsa Kalbacher, Corinne Delcambre, Emmanuelle Bompas, Olivier Collard, Nicolás Isambert, Cécile Guillemet, María Rios, Martina Sundqvist, Florence Duffaud

2021Annals of Oncology14 citationsDOI

Topics & Concepts

TrabectedinMedicineDoxorubicinOncologyPhases of clinical researchInternal medicineChemotherapySurgerySoft tissue sarcomaSoft tissueSarcoma Diagnosis and TreatmentGastrointestinal Tumor Research and TreatmentSoft tissue tumors and treatment
LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study | Litcius